On March 26, 2024, TAG presented this webinar that discusses implementing long-lasting injectable PrEP treatments and the evolving landscape of HIV prevention.
These two policy briefs explore two as yet untapped sources for drug-resistant tuberculosis (DR-TB) research funding within the U.S. Department of Health and Human Services (HHS).
On February 27, 2024, TAG explored innovative strategies and successful interventions for addressing the unique challenges faced by people living with HIV who are experiencing homelessness.
Treatment Action Group (TAG), the New-York-City-based activist research and policy think tank working to end the epidemics of HIV, TB, and hepatitis C, made leadership changes at its annual Board of Directors meeting on February 10, 2024.
Our annual Research in Action Awards (RIAA) event is TAG’s biggest night of the year. On October 19, we’ll be deeply honored to gather with our most cherished supporters and community members to recognize just a few of the many visionaries whose work has brought us closer to ending HIV, TB, and HCV.
We're excited to welcome Dr. Jeanne Marazzo as the first woman and openly LGBTQ+ Director of the National Institute of Allergy and Infectious Diseases (NIAID).
TAG is presenting the exhibition “35 Years of Art to End AIDS” at Melissa Morgan Fine Art in Palm Desert, California, from March 17 through April 7, 2023. This exhibit features selected works form our Limited Art Editions collection.
For Us By Us: PrEP in Black America, A Master Plan for HIV Prevention in Black America is a collaborative project from the PrEP in Black America coalition, which includes Treatment Action Group, PrEP4All, AVAC, Atlanta Black Women Leaders on PrEP, Equity & Impact Solutions, iStrive, Positive Impact Health Centers, and Red Hot.
Comment submitted prior to their meeting on November 17, 2022. Comment is in regard to discussion and voting on recommendation related to implementation of the HIV Organ Policy Equity (HOPE) Act of 2013, specifically pertaining to HIV-positive to HIV-positive organ transplantation and pertaining to the following draft recommendation under consideration regarding removal of the statutory “NIH Research Criteria and IRB” requirement.